16 August 2023 - Another underwhelming agenda that was only published after agitation on social media.

The agenda for this week's PTAC meeting has finally been published. There is no application for a cancer medicine.

• Empagliflozin - type 2 diabetes mellitus (restriction change)
• Empagliflozin - renal failure (new indication)
• Tocilizumab - giant cell arteritis (new indication)
• Infliximab SC - multiple indications (new formulation)
• Ofatumumab - multiple sclerosis (new medicine)
• Poly pill - unclear
• Food thickeners - review

Read PTAC agenda